$1.26
+0.05 (+3.70%)
Open$1.24
Previous Close$1.22
Day High$1.29
Day Low$1.22
52W High$1.88
52W Low$1.02
Volume—
Avg Volume374.7K
Market Cap65.06M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+452.4% upside
Current
$1.26
$1.26
Target
$6.96
$6.96
$5.52
$6.96 avg
$10.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.44M | 13.53M | 15.01M |
| Net Income | -947,825 | -765,390 | -987,033 |
| Profit Margin | -6.6% | -5.7% | -6.6% |
| EBITDA | -1,267,375 | -1,123,871 | -1,333,015 |
| Free Cash Flow | -656,212 | -624,188 | -715,122 |
| Rev Growth | +21.5% | +1.8% | +6.7% |
| Debt/Equity | 0.93 | 0.92 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |